Clinical Trial Update: Efficacy and Safety of Fixed Dose Combination (FDC) of Olopatadine Hydrochloride and Mometasone Furoate Nasal Spray (Molo; Also Referred as GSP 301) in the Treatment of Seasonal Allergic Rhinitis (SAR) [Phase 2]

View source ↗

Summary

A Phase 2 study assessed the efficacy and safety of the fixed-dose combination nasal spray olopatadine hydrochloride and mometasone furoate (Molo/GSP 301) for s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Seasonal Allergic Rhinitis

Drugs mentioned

• Molo (GSP 301) fixed-dose combination nasal spray (olopatadine hydrochloride and mometasone furoate)

Snippet

Sponsor: Glenmark Pharmaceuticals Ltd. India | Conditions: Seasonal Allergic Rhinitis | Phase 2 | Status: COMPLETED